 John Hamner
Concepts (153)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasm Recurrence, Local | 4 | 2025 | 1079 | 0.870 |
Why?
| | Neuroblastoma | 8 | 2009 | 160 | 0.840 |
Why?
| | Interferon-beta | 7 | 2010 | 92 | 0.640 |
Why?
| | Gastric Outlet Obstruction | 1 | 2019 | 12 | 0.630 |
Why?
| | Carcinoma, Signet Ring Cell | 1 | 2019 | 15 | 0.630 |
Why?
| | Duodenal Neoplasms | 1 | 2019 | 23 | 0.620 |
Why?
| | Carcinoma, Lobular | 1 | 2019 | 49 | 0.600 |
Why?
| | Melanoma | 5 | 2025 | 760 | 0.540 |
Why?
| | Urologic Neoplasms | 1 | 2017 | 31 | 0.540 |
Why?
| | Skin Neoplasms | 5 | 2025 | 855 | 0.520 |
Why?
| | Hepatectomy | 1 | 2017 | 251 | 0.470 |
Why?
| | Sentinel Lymph Node Biopsy | 3 | 2025 | 115 | 0.470 |
Why?
| | Neoplasms, Second Primary | 1 | 2015 | 118 | 0.440 |
Why?
| | Pancreaticoduodenectomy | 1 | 2015 | 164 | 0.440 |
Why?
| | Neovascularization, Pathologic | 5 | 2010 | 301 | 0.400 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2015 | 289 | 0.380 |
Why?
| | Breast Neoplasms | 2 | 2019 | 2253 | 0.370 |
Why?
| | Adenocarcinoma | 2 | 2015 | 940 | 0.360 |
Why?
| | Liver Neoplasms | 1 | 2017 | 786 | 0.350 |
Why?
| | Genetic Therapy | 3 | 2008 | 297 | 0.320 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2010 | 872 | 0.300 |
Why?
| | Gene Expression Profiling | 2 | 2025 | 1774 | 0.280 |
Why?
| | Hydroxamic Acids | 1 | 2008 | 89 | 0.280 |
Why?
| | Pancreatic Neoplasms | 1 | 2015 | 938 | 0.270 |
Why?
| | Boronic Acids | 1 | 2007 | 37 | 0.270 |
Why?
| | Lymphedema | 1 | 2007 | 24 | 0.260 |
Why?
| | Pyrazines | 1 | 2007 | 90 | 0.260 |
Why?
| | Soft Tissue Neoplasms | 1 | 2007 | 115 | 0.250 |
Why?
| | Mice, SCID | 9 | 2010 | 367 | 0.250 |
Why?
| | Pain, Postoperative | 1 | 2007 | 265 | 0.220 |
Why?
| | Antineoplastic Agents | 5 | 2007 | 2129 | 0.220 |
Why?
| | Combined Modality Therapy | 3 | 2015 | 1236 | 0.210 |
Why?
| | Disease-Free Survival | 3 | 2025 | 686 | 0.200 |
Why?
| | Head and Neck Neoplasms | 2 | 2018 | 606 | 0.190 |
Why?
| | Aged | 10 | 2025 | 23961 | 0.180 |
Why?
| | Radiation Tolerance | 2 | 2010 | 96 | 0.160 |
Why?
| | Stem Cells | 3 | 2009 | 594 | 0.160 |
Why?
| | Neoplasm Staging | 3 | 2018 | 1389 | 0.140 |
Why?
| | Cell Line, Tumor | 8 | 2010 | 3412 | 0.140 |
Why?
| | Tumor Burden | 4 | 2018 | 309 | 0.140 |
Why?
| | In Vitro Techniques | 3 | 2009 | 1092 | 0.140 |
Why?
| | Angiogenesis Inhibitors | 2 | 2010 | 229 | 0.130 |
Why?
| | Prognosis | 4 | 2025 | 4030 | 0.130 |
Why?
| | Erlotinib Hydrochloride | 1 | 2015 | 72 | 0.120 |
Why?
| | Follow-Up Studies | 3 | 2017 | 5131 | 0.120 |
Why?
| | Bone Neoplasms | 2 | 2009 | 247 | 0.120 |
Why?
| | Postoperative Complications | 1 | 2007 | 2654 | 0.110 |
Why?
| | Adenoviridae | 4 | 2008 | 193 | 0.110 |
Why?
| | Gastrointestinal Stromal Tumors | 1 | 2015 | 38 | 0.110 |
Why?
| | Sentinel Lymph Node | 2 | 2025 | 45 | 0.110 |
Why?
| | Deoxycytidine | 1 | 2015 | 179 | 0.110 |
Why?
| | Lymph Nodes | 1 | 2017 | 491 | 0.110 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2015 | 77 | 0.110 |
Why?
| | Female | 11 | 2025 | 73304 | 0.110 |
Why?
| | Humans | 21 | 2025 | 137585 | 0.110 |
Why?
| | Middle Aged | 9 | 2025 | 33479 | 0.110 |
Why?
| | Thyroid Neoplasms | 1 | 2018 | 343 | 0.110 |
Why?
| | Immunotherapy | 1 | 2018 | 641 | 0.100 |
Why?
| | Stomach Neoplasms | 1 | 2014 | 122 | 0.100 |
Why?
| | Male | 15 | 2025 | 67762 | 0.100 |
Why?
| | Healthcare Disparities | 1 | 2018 | 654 | 0.090 |
Why?
| | Health Status Disparities | 1 | 2014 | 289 | 0.090 |
Why?
| | Mice | 11 | 2010 | 17787 | 0.090 |
Why?
| | Retrospective Studies | 5 | 2018 | 15657 | 0.090 |
Why?
| | Lymphatic Metastasis | 2 | 2025 | 352 | 0.090 |
Why?
| | Rhabdomyosarcoma, Alveolar | 1 | 2010 | 11 | 0.080 |
Why?
| | Oxygen Consumption | 2 | 2010 | 696 | 0.080 |
Why?
| | Osteoprotegerin | 1 | 2009 | 24 | 0.080 |
Why?
| | Transcriptome | 2 | 2025 | 971 | 0.070 |
Why?
| | Antineoplastic Agents, Alkylating | 1 | 2008 | 73 | 0.070 |
Why?
| | Cyclophosphamide | 1 | 2008 | 247 | 0.070 |
Why?
| | Subcutaneous Tissue | 1 | 2007 | 24 | 0.070 |
Why?
| | Bortezomib | 1 | 2007 | 54 | 0.070 |
Why?
| | Stockings, Compression | 1 | 2007 | 5 | 0.070 |
Why?
| | Skin Care | 1 | 2007 | 25 | 0.070 |
Why?
| | Topotecan | 1 | 2007 | 13 | 0.070 |
Why?
| | Random Allocation | 1 | 2008 | 353 | 0.070 |
Why?
| | Probability | 1 | 2008 | 304 | 0.070 |
Why?
| | Adult | 7 | 2025 | 37929 | 0.060 |
Why?
| | Neoplasm Transplantation | 4 | 2007 | 257 | 0.060 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 1692 | 0.060 |
Why?
| | Animals | 11 | 2010 | 36940 | 0.060 |
Why?
| | Neoplasm Metastasis | 1 | 2009 | 658 | 0.060 |
Why?
| | Drainage | 1 | 2007 | 173 | 0.060 |
Why?
| | Diphosphonates | 1 | 2006 | 66 | 0.060 |
Why?
| | Treatment Outcome | 2 | 2018 | 10811 | 0.060 |
Why?
| | Bone Density Conservation Agents | 1 | 2006 | 80 | 0.060 |
Why?
| | Glioma | 1 | 2010 | 395 | 0.060 |
Why?
| | Clinical Protocols | 1 | 2007 | 271 | 0.060 |
Why?
| | Blood Vessels | 1 | 2007 | 187 | 0.060 |
Why?
| | Imidazoles | 1 | 2006 | 238 | 0.060 |
Why?
| | Disease Models, Animal | 4 | 2008 | 4295 | 0.060 |
Why?
| | Blotting, Western | 1 | 2008 | 1226 | 0.060 |
Why?
| | Analgesics | 1 | 2007 | 206 | 0.060 |
Why?
| | Cell Proliferation | 2 | 2010 | 2475 | 0.060 |
Why?
| | Proportional Hazards Models | 2 | 2018 | 1266 | 0.060 |
Why?
| | Pain Measurement | 1 | 2007 | 521 | 0.060 |
Why?
| | Unnecessary Procedures | 1 | 2025 | 50 | 0.060 |
Why?
| | Antibodies, Monoclonal | 2 | 2010 | 1430 | 0.050 |
Why?
| | Aged, 80 and over | 2 | 2025 | 7635 | 0.050 |
Why?
| | Sensitivity and Specificity | 1 | 2008 | 1946 | 0.050 |
Why?
| | Risk Factors | 1 | 2017 | 10388 | 0.050 |
Why?
| | Prospective Studies | 2 | 2025 | 7604 | 0.050 |
Why?
| | United States | 5 | 2018 | 14841 | 0.050 |
Why?
| | Antiviral Agents | 1 | 2008 | 744 | 0.050 |
Why?
| | Exercise Therapy | 1 | 2007 | 443 | 0.050 |
Why?
| | Genetic Vectors | 3 | 2008 | 319 | 0.050 |
Why?
| | Chronic Disease | 1 | 2007 | 1793 | 0.040 |
Why?
| | Neurons | 1 | 2008 | 1590 | 0.040 |
Why?
| | Bevacizumab | 2 | 2010 | 138 | 0.040 |
Why?
| | Biomarkers, Tumor | 1 | 2025 | 1276 | 0.030 |
Why?
| | Transduction, Genetic | 2 | 2009 | 127 | 0.030 |
Why?
| | Injections, Intravenous | 2 | 2008 | 206 | 0.030 |
Why?
| | California | 1 | 2018 | 431 | 0.030 |
Why?
| | Lymph Node Excision | 1 | 2017 | 171 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2018 | 889 | 0.030 |
Why?
| | Drug Delivery Systems | 2 | 2008 | 365 | 0.030 |
Why?
| | SEER Program | 1 | 2014 | 227 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2018 | 1289 | 0.030 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2010 | 804 | 0.030 |
Why?
| | Comorbidity | 1 | 2018 | 1622 | 0.030 |
Why?
| | Databases, Factual | 1 | 2018 | 1357 | 0.020 |
Why?
| | Sex Factors | 1 | 2018 | 2071 | 0.020 |
Why?
| | Neoplasms | 1 | 2007 | 2671 | 0.020 |
Why?
| | Age Factors | 1 | 2018 | 3295 | 0.020 |
Why?
| | Disease Progression | 2 | 2009 | 2757 | 0.020 |
Why?
| | Radiation-Sensitizing Agents | 1 | 2010 | 43 | 0.020 |
Why?
| | Survival Rate | 1 | 2014 | 1972 | 0.020 |
Why?
| | Radiation, Ionizing | 1 | 2010 | 80 | 0.020 |
Why?
| | Registries | 1 | 2018 | 2035 | 0.020 |
Why?
| | Young Adult | 2 | 2018 | 13209 | 0.020 |
Why?
| | Transplantation, Heterologous | 1 | 2010 | 194 | 0.020 |
Why?
| | Cell Hypoxia | 1 | 2010 | 226 | 0.020 |
Why?
| | Incidence | 1 | 2015 | 2804 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2009 | 431 | 0.020 |
Why?
| | Angiopoietin-1 | 1 | 2007 | 11 | 0.020 |
Why?
| | Cohort Studies | 1 | 2018 | 5742 | 0.020 |
Why?
| | Green Fluorescent Proteins | 1 | 2009 | 390 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2018 | 5472 | 0.020 |
Why?
| | Dependovirus | 1 | 2007 | 68 | 0.020 |
Why?
| | Microcirculation | 1 | 2007 | 149 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2010 | 1353 | 0.020 |
Why?
| | Pressure | 1 | 2007 | 225 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2007 | 545 | 0.010 |
Why?
| | Time Factors | 1 | 2014 | 6828 | 0.010 |
Why?
| | Cell Movement | 1 | 2007 | 967 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2006 | 2057 | 0.010 |
Why?
| | Cell Line | 1 | 2007 | 2847 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2008 | 4193 | 0.010 |
Why?
| | Hypoxia | 1 | 2007 | 1112 | 0.010 |
Why?
| | Cytokines | 1 | 2007 | 2085 | 0.010 |
Why?
| | Phenotype | 1 | 2007 | 3196 | 0.010 |
Why?
| | Apoptosis | 1 | 2006 | 2553 | 0.010 |
Why?
|
|
Hamner's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|